P=N/A, N=1470, Recruiting, Maastricht University Medical Center | Not yet recruiting --> Recruiting | N=820 --> 1470

P1, N=10, Not yet recruiting, Johns Hopkins University

P1, N=85, Recruiting, Medical University of Vienna

P=N/A, N=120, Recruiting, Northwell Health

P4, N=400, Recruiting, The Chaim Sheba Medical Center | Trial completion date: Aug 2024 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2027

P2, N=46, Completed, Hasanuddin University

We demonstrate that CPZ, alone or in combination with temozolomide (TMZ), the current standard of care, activates the cGAS-STING signaling pathway, thus promoting anti-tumor immune responses. This study uncovers that CPZ exerts a previously unrecognized anti-cancer immunomodulatory activity, remodeling the immune microenvironment and enhancing the anti-tumor immune response. By overcoming TMZ resistance, CPZ not only exerts a direct anti-neoplastic effect, but also sensitizes GBM cells to standard therapy.

This further suggests that if chlorpromazine binding alters coupling between the PAS/CNBH domain ring, VSD and pore, as predicted by the network analysis, these alterations occur at potential more depolarized than the ones eliciting the Cole-Moore shift. Taken together, our study provides an insight into the allosteric pathways of EAG1 channel regulation by small molecule PAS domain binders.

P4, N=31, Completed, Vanderbilt University Medical Center | Recruiting --> Completed | N=350 --> 31

P=N/A, N=104, Not yet recruiting, Huashan Hospital Fudan University; Huashan Hospital Fudan University

P2, N=128, Not yet recruiting, University of Calgary | N=36 --> 128 | Trial completion date: Oct 2027 --> Jan 2028 | Trial primary completion date: Sep 2027 --> Dec 2027

P4, N=60, Completed, All India Institute of Medical Sciences, Bhubaneswar | Recruiting --> Completed